“The mechanism that PPMOs use to kill bacteria is revolutionary”
Researchers at Oregon State University and other institutions today announced the successful use of a new type of antibacterial agent called a PPMO, which appears to function as well or better than an antibiotic, but may be more precise and also solve problems with antibiotic resistance.
In animal studies, one form of PPMO showed significant control of two strains of Acinetobacter, a group of bacteria of global concern that has caused significant mortality among military personnel serving in Middle East combat.
The new PPMOs offer a fundamentally different attack on bacterial infection, researchers say.
They specifically target the underlying genes of a bacterium, whereas conventional antibiotics just disrupt its cellular function and often have broader, unwanted impacts. As they are further developed, PPMOs should offer a completely different and more precise approach to managing bacterial infection, or conceptually almost any disease that has an underlying genetic component.
The findings were published today in the Journal of Infectious Diseases, by researchers from OSU, the University of Texas Southwestern Medical Center, and Sarepta, Inc., a Corvallis, Ore., firm.
“The mechanism that PPMOs use to kill bacteria is revolutionary,” said Bruce Geller, a professor of microbiology in the OSU College of Science and lead author on the study. “They can be synthesized to target almost any gene, and in that way avoid the development of antibiotic resistance and the negative impacts sometimes associated with broad-spectrum antibiotics.
“Molecular medicine,” Geller said, “is the way of the future.”
PPMO stands for a peptide-conjugated phosphorodiamidate morpholino oligomer – a synthetic analog of DNA or RNA that has the ability to silence the expression of specific genes. Compared to conventional antibiotics, which are often found in nature, PPMOs are completely synthesized in the laboratory with a specific genetic target in mind.
In animal laboratory tests against A. baumannii, one of the most dangerous Acinetobacter strains, PPMOs were far more powerful than some conventional antibiotics like ampicillin, and comparable to the strongest antibiotics available today. They were also effective in cases where the bacteria were resistant to antibiotics.
PPMOs have not yet been tested in humans. However, their basic chemical structure, the PMO, has been extensively tested in humans and found safe. Although the addition of the peptide to the PPMO poses an uncertain risk of toxicity, the potency of PPMOs reduces the risk while greatly improving delivery of the PMOs into bacterial cells, Geller said.
The Latest on: PPMO
FCAN apprises PPMO of the hike in price of construction materials
on March 14, 2018 at 8:40 pm
KATHMANDU, March 15: A team of the Federation of Contractors' Association of Nepal (FCAN) has drawn the attention of the Public Procurement Monitoring Office (PPMO) toward unnatural hike in prices of some construction materials in the market. It also ... […]
Sarepta Therapeutics' (SRPT) CEO Douglas Ingram on Q4 2017 Results - Earnings Call Transcript
on March 1, 2018 at 10:54 pm
We received an IND for our internally RNA targeted PPMO candidate SRP-5051 and we advance five additional PPMOs into IND enabling preclinical programs, and we successfully strengthened our cash position so that we exited 2017 with nearly 1.1 billion on our ... […]
Tourism secy Neupane transferred to PPMO
on January 26, 2018 at 9:15 pm
The Cabinet meeting on Thursday transferred secretary at the Ministry of Culture, Tourism and Civil Aviation (MoCTCA) Maheswor Neupane to the Public Procurement Monitoring Office (PPMO). It has been learnt that Tourism Minister Jitendra Narayan Dev took ... […]
BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
on November 7, 2017 at 12:52 am
* Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51 Source text for Eikon: Further company coverage: […]
Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
on November 7, 2017 at 12:30 am
Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical ... application for the Company's peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051. Sarepta will immediately ... […]
via Google News and Bing News